Glancy Prongay & Murray LLP Continues Its Investigation on Behalf of Baxter International Inc. Investors
14 nov. 2019 16h00 HE
|
Glancy Prongay & Murray LLP
LOS ANGELES, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX)...
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation on Behalf of Baxter International Inc. Investors
14 nov. 2019 12h45 HE
|
Law Offices of Howard G. Smith
BENSALEM, Pa., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) investors...
Bragar Eagel & Squire, P.C. Is Investigating Merit Medical Systems, Baxter International, Under Armour, and BeiGene on Behalf of Stockholders and Encourages Investors to Contact the Firm
06 nov. 2019 10h58 HE
|
Bragar Eagel & Squire
NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, is investigating potential claims against Merit Medical Systems, Inc....
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation on Behalf of Baxter International Inc. Investors
05 nov. 2019 12h17 HE
|
Law Offices of Howard G. Smith
BENSALEM, Pa., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX) investors...
Glancy Prongay & Murray LLP Continues Its Investigation on Behalf of Baxter International Inc. Investors
31 oct. 2019 14h04 HE
|
Glancy Prongay & Murray LLP
LOS ANGELES, Oct. 31, 2019 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf of Baxter International Inc. (“Baxter” or the “Company”) (NYSE: BAX)...
PharmaCyte Biotech's "Factory" of Live Cells Takes Direct Aim at Cancer Tumors Armed With FDA Orphan Drug Status
18 mars 2015 09h00 HE
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - March 18, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is aiming directly at the problem patients with advanced pancreatic cancer face, an inoperable tumor! PharmaCyte owns...
Melinta Therapeutics Bolsters Executive Team with Appointment of Paul Estrem as Chief Financial Officer
02 déc. 2013 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Melinta Therapeutics today
announced the appointment of Paul Estrem to the role of chief
financial officer. Mr. Estrem brings more than 20 years...